CMC Biologics A/S Announce Manufacturing Agreement with Symphogen A/S
CMC Biologics A/S announced that it has entered into an agreement with Symphogen A/S for process development and cGMP manufacture of an undisclosed polyclonal antibody product candidate from Symphogen's development pipeline. Terms of the agreement were not disclosed.
"We are pleased to establish such a partnership with Symphogen and are excited to be involved in this unique field of recombinant polyclonal antibody technology," said Mads Laustsen, CEO of CMC.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.